US6685940B2
(en)
*
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6267958B1
(en)
*
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US5783186A
(en)
*
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
CN1214044C
(zh)
*
|
1996-03-27 |
2005-08-10 |
基因技术股份有限公司 |
ErbB3抗体
|
US5968511A
(en)
*
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
EP0910407B1
(de)
*
|
1996-05-15 |
2003-02-26 |
Altarex Corp. |
Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten
|
US8038994B2
(en)
*
|
1996-05-15 |
2011-10-18 |
Quest Pharmatech Inc. |
Combination therapy for treating disease
|
US20060159688A1
(en)
*
|
1996-05-15 |
2006-07-20 |
Ragupathy Madiyalakan |
Method for diagnosing efficacy of xenotypic antibody therapy
|
US20080220012A1
(en)
*
|
1996-05-15 |
2008-09-11 |
Ragupathy Madiyalakan |
Therapeutic Compositions that alter the immune response
|
US7371376B1
(en)
*
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
TR199901615T2
(en)
*
|
1996-10-18 |
1999-11-22 |
Genentech, Inc. |
Anti-ErbB2 antikorlar�.
|
US6270980B1
(en)
|
1997-06-05 |
2001-08-07 |
Idun Pharmaceuticals, Inc. |
Rapid methods for identifying modifiers of cellular apoptosis activity
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
AU765003B2
(en)
*
|
1998-03-27 |
2003-09-04 |
Genentech Inc. |
Apo-2 ligand-anti-her-2 antibody synergism
|
FR2780062B1
(fr)
*
|
1998-06-17 |
2000-07-28 |
Rhone Poulenc Rorer Sa |
Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
|
US7396810B1
(en)
*
|
2000-08-14 |
2008-07-08 |
Oregon Health Sciences University |
Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
|
US7625859B1
(en)
*
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
ATE425749T1
(de)
|
1999-01-27 |
2009-04-15 |
Cornell Res Foundation Inc |
Behandlung von mit her-2/neu-uberexprimierung einhergehendem krebs
|
JP4794049B2
(ja)
*
|
1999-04-06 |
2011-10-12 |
ジェネンテック, インコーポレイテッド |
糖尿病治療へのErbBレセプターリガンドの使用
|
US7041292B1
(en)
*
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
EP2112167A3
(de)
|
1999-06-25 |
2010-12-22 |
Genentech, Inc. |
Humanisierte ANTI-ERBB2-Antikörper und Behandlung mit ANTI-ERBB2-Antikörpern
|
DK2283866T3
(en)
|
1999-06-25 |
2015-05-18 |
Genentech Inc |
METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
JP4579471B2
(ja)
*
|
1999-06-25 |
2010-11-10 |
ジェネンテック, インコーポレイテッド |
抗ErbB2抗体を用いる前立腺癌の処置
|
ATE438411T1
(de)
*
|
1999-08-27 |
2009-08-15 |
Genentech Inc |
Dosierung für die behandlung mit anti erbb2- antikörpern
|
EP2289549A3
(de)
|
1999-10-01 |
2011-06-15 |
Immunogen, Inc. |
Immunokonjugate für Krebsbehandlung
|
US20050100542A1
(en)
*
|
1999-10-08 |
2005-05-12 |
Young David S. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US8048416B2
(en)
*
|
1999-10-08 |
2011-11-01 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US20040105816A1
(en)
*
|
1999-10-08 |
2004-06-03 |
Young David S. F. |
Cancerous disease modifying antibodies
|
US6794494B1
(en)
|
2003-04-14 |
2004-09-21 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7256271B2
(en)
|
2003-01-21 |
2007-08-14 |
Arius Research Inc. |
Cancerous disease modifying antibodies
|
US7189397B2
(en)
*
|
1999-10-08 |
2007-03-13 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US20090004103A1
(en)
*
|
1999-10-08 |
2009-01-01 |
Young David S F |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US20080124327A1
(en)
*
|
1999-10-08 |
2008-05-29 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US7419792B2
(en)
*
|
1999-10-08 |
2008-09-02 |
Arius Research Inc. |
Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
|
US6180357B1
(en)
|
1999-10-08 |
2001-01-30 |
Arius Research, Inc. |
Individualized patient-specific anti-cancer antibodies
|
US7442776B2
(en)
*
|
1999-10-08 |
2008-10-28 |
Young David S F |
Cancerous disease modifying antibodies
|
US6657048B2
(en)
*
|
1999-10-08 |
2003-12-02 |
Arius Research, Inc. |
Individualized anti-cancer antibodies
|
US20040001789A1
(en)
*
|
1999-10-08 |
2004-01-01 |
Young David S. F. |
Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
|
US7947496B2
(en)
|
1999-10-08 |
2011-05-24 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US8071072B2
(en)
*
|
1999-10-08 |
2011-12-06 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US7252821B2
(en)
|
1999-10-08 |
2007-08-07 |
Arius Research Inc. |
Cancerous disease modifying antibodies
|
EP1118334A1
(de)
*
|
2000-01-11 |
2001-07-25 |
Aventis Behring Gesellschaft mit beschränkter Haftung |
Verfahren zur Herstellung von Konjugate zur Behändlung von Allergien und Autoimmunkrankheiten
|
US6632979B2
(en)
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
DK2857516T3
(en)
*
|
2000-04-11 |
2017-08-07 |
Genentech Inc |
Multivalent antibodies and uses thereof
|
WO2001083781A2
(en)
*
|
2000-04-28 |
2001-11-08 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
ATE441433T1
(de)
*
|
2000-05-19 |
2009-09-15 |
Genentech Inc |
Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine krebstherapie mit einem erbb- antagonisten
|
US7358353B2
(en)
*
|
2000-08-22 |
2008-04-15 |
Agensys, Inc. |
Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
|
ES2281437T3
(es)
*
|
2000-08-22 |
2007-10-01 |
Agensys, Inc. |
Acido nucleico y proteina correspondiente denominada 158p1d7 util para el tratamiento y la deteccion del cancer de vejiga y otros canceres.
|
US7361343B2
(en)
*
|
2003-01-21 |
2008-04-22 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
US7431923B2
(en)
*
|
2005-01-03 |
2008-10-07 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
US20060210474A1
(en)
*
|
2000-11-29 |
2006-09-21 |
Young David S |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
US7442777B2
(en)
*
|
2000-11-29 |
2008-10-28 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
US7009040B2
(en)
*
|
2003-01-21 |
2006-03-07 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7534429B2
(en)
*
|
2000-11-29 |
2009-05-19 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
AU2002249170B2
(en)
*
|
2001-02-02 |
2007-02-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V |
Method for identifying functional nucleic acids
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
WO2003074674A2
(en)
*
|
2002-03-01 |
2003-09-12 |
Exelixis, Inc. |
MSRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
|
SI2289942T1
(sl)
|
2002-04-10 |
2013-11-29 |
Genentech, Inc. |
Variante protitelesa proti HER2
|
US20050260208A1
(en)
*
|
2002-04-11 |
2005-11-24 |
Altarex Medical Corp. |
Binding agents and their use in targeting tumor cells
|
MXPA05000403A
(es)
*
|
2002-07-15 |
2005-07-22 |
Genentech Inc |
Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2.
|
ES2368733T3
(es)
|
2002-07-18 |
2011-11-21 |
Merus B.V. |
Producción recombinante de mezclas de anticuerpos.
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
AU2003295798B2
(en)
*
|
2002-11-21 |
2009-09-10 |
Genentech, Inc. |
Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
|
US7361342B2
(en)
*
|
2003-01-21 |
2008-04-22 |
Arius Research Inc. |
Cancerous disease modifying antibodies
|
US7393531B2
(en)
*
|
2003-01-21 |
2008-07-01 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of MCSP
|
US7468254B2
(en)
*
|
2003-01-21 |
2008-12-23 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of MCSP
|
US7488475B2
(en)
|
2003-01-21 |
2009-02-10 |
Arius Research, Inc. |
Antibody therapy of tumors
|
US7175846B2
(en)
*
|
2003-01-21 |
2007-02-13 |
Arius Research Inc. |
Cancerous disease modifying antibodies
|
US7195764B2
(en)
|
2003-04-14 |
2007-03-27 |
Arius Research Inc. |
Cancerous disease modifying antibodies
|
US7399835B2
(en)
*
|
2004-02-26 |
2008-07-15 |
Arius Research Inc. |
Cancerous disease modifying antibodies
|
US20080025977A1
(en)
*
|
2003-04-14 |
2008-01-31 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD59
|
US20060140963A1
(en)
*
|
2003-04-14 |
2006-06-29 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD59
|
US20080213169A1
(en)
*
|
2003-04-14 |
2008-09-04 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD59
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
CA2527694C
(en)
|
2003-05-30 |
2015-07-14 |
Hendricus Renerus Jacobus Mattheus Hoogenboom |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
US20050008649A1
(en)
*
|
2003-06-02 |
2005-01-13 |
University Of Miami |
Chimeric molecules and methods of use
|
US20040254108A1
(en)
*
|
2003-06-13 |
2004-12-16 |
Jing Ma |
Preparation and application of anti-tumor bifunctional fusion proteins
|
US20050232931A1
(en)
*
|
2003-06-13 |
2005-10-20 |
Oncomax Acquisition Corp. |
Preparation and application of anti-tumor bifunctional fusion proteins
|
PL1648998T3
(pl)
|
2003-07-18 |
2015-03-31 |
Amgen Inc |
Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
|
US20050027106A1
(en)
*
|
2003-07-28 |
2005-02-03 |
Young David S. F. |
Cancerous disease modifying antibodies
|
WO2005014618A2
(en)
*
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
KR101438983B1
(ko)
|
2003-11-06 |
2014-09-05 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
CA2554054C
(en)
|
2004-01-20 |
2013-06-04 |
Merus B.V. |
Mixtures of binding proteins
|
US7348413B2
(en)
*
|
2004-02-26 |
2008-03-25 |
Arius Research Inc. |
Cancerous disease modifying antibodies
|
US20050255041A1
(en)
*
|
2004-05-13 |
2005-11-17 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
AU2005249490B2
(en)
|
2004-06-01 |
2010-07-29 |
Genentech, Inc. |
Antibody drug conjugates and methods
|
SV2006002143A
(es)
*
|
2004-06-16 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del cancer resistente al platino
|
MXPA06014684A
(es)
|
2004-06-18 |
2007-02-12 |
Ambrx Inc |
Novedosos polipeptidos de enlace antigeno y sus usos.
|
KR20180091967A
(ko)
|
2004-07-22 |
2018-08-16 |
제넨테크, 인크. |
Her2 항체 조성물
|
EP1778728A2
(de)
*
|
2004-08-19 |
2007-05-02 |
Genentech, Inc. |
Polypeptidvarianten mit veränderten effektorfunktionen
|
US7394210B2
(en)
*
|
2004-09-29 |
2008-07-01 |
Tir Technology Lp |
System and method for controlling luminaires
|
US20080206231A1
(en)
*
|
2004-10-05 |
2008-08-28 |
Oregon Health And Science University |
Compositions and Methods for Treating Disease
|
JO3000B1
(ar)
*
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
RU2007125644A
(ru)
*
|
2004-12-07 |
2009-01-20 |
Дженентек Инк. (Us) |
Отбор пациентов для терапии ингибитором her
|
EP1752471B9
(de)
|
2005-01-05 |
2009-04-15 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften
|
CN101141981A
(zh)
|
2005-01-21 |
2008-03-12 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
RU2007133660A
(ru)
*
|
2005-02-09 |
2009-03-20 |
Дженентек, Инк. (Us) |
Ингибирование шеддинга her2 антагонистами матриксной металлопротеиназы
|
EP2399605A1
(de)
*
|
2005-02-23 |
2011-12-28 |
Genentech, Inc. |
Ausdehnungszeit einer Krankheitsprogression oder -überlebens bei Krebspatienten
|
TW200642695A
(en)
*
|
2005-03-08 |
2006-12-16 |
Genentech Inc |
Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
US7411046B2
(en)
|
2005-08-02 |
2008-08-12 |
Arius Research Inc |
Cancerous disease modifying antibodies
|
US7452978B2
(en)
|
2005-08-02 |
2008-11-18 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7494648B2
(en)
*
|
2005-08-02 |
2009-02-24 |
Hoffmann-La Roche Inc. |
Cancerous disease modifying antibodies
|
US7456258B2
(en)
|
2005-08-02 |
2008-11-25 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7456259B2
(en)
|
2005-08-02 |
2008-11-25 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7452979B2
(en)
|
2005-08-02 |
2008-11-18 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
FR2895086B1
(fr)
*
|
2005-12-16 |
2012-10-05 |
Lab Francais Du Fractionnement |
Potentialisation de l'apoptose par des anticorps monoclonaux
|
CA2643063A1
(en)
|
2006-02-24 |
2007-08-30 |
Arius Research, Inc. |
Cancerous disease modifying antibody 141205-02
|
US7420040B2
(en)
*
|
2006-02-24 |
2008-09-02 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
US20080305104A1
(en)
*
|
2006-02-24 |
2008-12-11 |
Young David S F |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
CA2643144A1
(en)
|
2006-02-24 |
2007-08-30 |
Arius Research, Inc. |
Cancerous disease modifying antibody 141205-04
|
US20080213267A1
(en)
*
|
2006-02-24 |
2008-09-04 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
US20080089891A1
(en)
*
|
2006-07-26 |
2008-04-17 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
PL2511301T3
(pl)
|
2006-08-04 |
2018-05-30 |
Medimmune Limited |
Ludzkie przeciwciała do ErbB2
|
KR20090101885A
(ko)
*
|
2006-11-13 |
2009-09-29 |
에프. 호프만-라 로슈 아게 |
암 질환 조절 항체
|
CA2668484A1
(en)
*
|
2006-11-13 |
2008-05-22 |
F. Hoffmann-La Roche Ag |
Cancerous disease modifying antibodies 180706-02
|
US20080241062A1
(en)
*
|
2006-11-13 |
2008-10-02 |
Young David S F |
Cancerous disease modifying antibodies
|
US20080206133A1
(en)
*
|
2007-01-23 |
2008-08-28 |
Young David S F |
Cancerous Disease Modifying Antibodies
|
US8003761B2
(en)
|
2007-01-23 |
2011-08-23 |
Hoffmann-La Roche Inc. |
Cancerous disease modifying antibodies
|
WO2008109440A2
(en)
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
CN101668849A
(zh)
*
|
2007-03-26 |
2010-03-10 |
霍夫曼-拉罗奇有限公司 |
由杂交瘤细胞系ar51a630.3产生的减轻癌性疾病的抗体010207-01
|
WO2008134876A1
(en)
*
|
2007-05-07 |
2008-11-13 |
F. Hoffmann-La Roche Ag |
Cancerous disease modifying antibodies
|
WO2008150485A2
(en)
*
|
2007-05-29 |
2008-12-11 |
Wyeth |
Erbb2 binding proteins and use thereof
|
US20090304590A1
(en)
*
|
2007-05-29 |
2009-12-10 |
Wyeth |
Therapeutic compositions and methods
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
CA3006428A1
(en)
|
2007-06-08 |
2008-12-18 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
ES2627223T3
(es)
|
2007-06-26 |
2017-07-27 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Presentación de agentes de unión
|
LT3327026T
(lt)
|
2007-07-09 |
2019-11-11 |
Genentech Inc |
Disulfidinio ryšio redukcijos prevencija rekombinantinių polipeptidų gaminimo metu
|
PT2176296E
(pt)
|
2007-07-16 |
2012-05-14 |
Genentech Inc |
Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
|
JP2010533495A
(ja)
|
2007-07-16 |
2010-10-28 |
ジェネンテック, インコーポレイテッド |
ヒト化CD79b抗体およびイムノコンジュゲートならびにそれらの使用
|
US8637026B2
(en)
*
|
2007-12-26 |
2014-01-28 |
Vaccinex, Inc. |
Anti-C35 antibody combination therapies and methods
|
CA2711256C
(en)
|
2008-01-03 |
2019-01-15 |
The Scripps Research Institute |
Antibody targeting through a modular recognition domain
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
US20090191197A1
(en)
*
|
2008-01-28 |
2009-07-30 |
Young David S F |
Cancerous disease modifying antibodies
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
MY157403A
(en)
|
2008-01-31 |
2016-06-15 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
ES2545977T3
(es)
|
2008-03-18 |
2015-09-17 |
Genentech, Inc. |
Combinaciones de un conjugado de anticuerpo-fármaco anti-HER2 y agentes quimioterapéuticos, y métodos de uso
|
US20090285751A1
(en)
*
|
2008-04-10 |
2009-11-19 |
Young David S F |
Cancerous disease modifying antibodies
|
JP4954326B2
(ja)
|
2008-04-11 |
2012-06-13 |
中外製薬株式会社 |
複数分子の抗原に繰り返し結合する抗原結合分子
|
EP2113255A1
(de)
*
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Zytotoxisches Immunglobulin
|
CA2724782A1
(en)
*
|
2008-05-19 |
2009-11-26 |
Takeda Pharmaceutical Company Limited |
An anti-cancer cytotoxic monoclonal antibody
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
EP2313437A1
(de)
*
|
2008-07-17 |
2011-04-27 |
Takeda Pharmaceutical Company Limited |
Antikörper, die krebserkrankungen modifizieren
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
US8734795B2
(en)
*
|
2008-10-31 |
2014-05-27 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
DK3903829T3
(da)
|
2009-02-13 |
2023-06-26 |
Immunomedics Inc |
Immunkonjugater med en intracellulær spaltelig binding
|
KR20130080871A
(ko)
|
2009-03-20 |
2013-07-15 |
제넨테크, 인크. |
이중특이적 항-her 항체
|
CN102421448A
(zh)
|
2009-05-29 |
2012-04-18 |
霍夫曼-拉罗奇有限公司 |
Her2信号传导调控剂在表达her2的胃癌患者中
|
WO2011004899A1
(en)
|
2009-07-06 |
2011-01-13 |
Takeda Pharmaceutical Company Limited |
Cancerous disease modifying antibodies
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
EP3431588A1
(de)
|
2009-08-11 |
2019-01-23 |
F. Hoffmann-La Roche AG |
Herstellung von proteinen in glutamin-freien zellkulturmedien
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
EP3009455A1
(de)
|
2009-09-16 |
2016-04-20 |
Immunomedics Inc. |
Klasse-i-anti-cea-antikörper und verwendungen davon
|
IN2012DN03354A
(de)
|
2009-12-02 |
2015-10-23 |
Immunomedics Inc |
|
SI2536748T1
(sl)
|
2010-02-18 |
2014-12-31 |
Genentech, Inc. |
Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka
|
EP2558501B1
(de)
|
2010-04-15 |
2016-09-07 |
Alper Biotech, Llc |
Monoklonale antikörper gegen her2-antigene und ihre verwendung
|
US9328024B2
(en)
|
2010-04-29 |
2016-05-03 |
The Regents Of The University Of California |
Application of high toughness, low viscosity nano-molecular resin for reinforcing pothole patching materials in asphalt and concrete base pavement
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
EP2407487A1
(de)
|
2010-07-14 |
2012-01-18 |
F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. |
Multispezifische modulare Antikörper
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
EP2643353A1
(de)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispezifische moleküle
|
EP4231014A3
(de)
|
2010-11-30 |
2024-03-20 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindende moleküle zur wiederholten bindung an mehrere antigenmoleküle
|
EP2655412B1
(de)
|
2010-12-21 |
2018-01-17 |
F. Hoffmann-La Roche AG |
Mit isoform angereicherte antikörperzubereitung und verfahren zu seiner herstellung
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
US20140093496A1
(en)
|
2011-02-25 |
2014-04-03 |
Chugai Seiyaku Kabushiki Kaisha |
Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
EP2704751B1
(de)
|
2011-05-02 |
2019-04-17 |
Immunomedics, Inc. |
Ultrafiltrationskonzentration ausgewählter allotypen-antikörper für kleinvolumige verabreichung
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
EP2546268A1
(de)
|
2011-07-13 |
2013-01-16 |
F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. |
Internalisierendes Immunglobulin
|
BR112014003431A2
(pt)
|
2011-08-17 |
2017-06-13 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
|
US20130084286A1
(en)
|
2011-08-31 |
2013-04-04 |
Thomas E. Januario |
Diagnostic markers
|
EP2762493B1
(de)
|
2011-09-30 |
2021-06-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
|
US9327023B2
(en)
|
2011-10-25 |
2016-05-03 |
The Regents Of The University Of Michigan |
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
|
AU2012346540C1
(en)
|
2011-11-30 |
2019-07-04 |
Genentech, Inc. |
ErbB3 mutations in cancer
|
EP2788500A1
(de)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identifizierung von non-respondern auf her2-inhibitoren
|
BR112014024017A8
(pt)
|
2012-03-27 |
2017-07-25 |
Genentech Inc |
Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
|
KR102382304B1
(ko)
|
2012-04-20 |
2022-04-04 |
메뤼스 엔.페. |
Ig-유사 분자의 제조방법 및 제조수단
|
EP2885002A4
(de)
|
2012-08-14 |
2016-04-20 |
Ibc Pharmaceuticals Inc |
Umleitung t-zell-bispezifischer antikörper zur behandlung von krankheiten
|
TR201900694T4
(tr)
|
2012-08-23 |
2019-02-21 |
Agensys Inc |
158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
|
AU2013337926B2
(en)
|
2012-10-30 |
2017-12-21 |
Esperance Pharmaceuticals, Inc. |
Antibody/drug conjugates and methods of use
|
CN104813168B
(zh)
|
2012-11-30 |
2017-10-20 |
霍夫曼-拉罗奇有限公司 |
需要pd‑l1抑制剂综合疗法的患者的鉴定
|
CA3177936A1
(en)
|
2012-12-13 |
2014-06-19 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
CA2907181C
(en)
|
2013-03-15 |
2023-10-17 |
Viktor Roschke |
Multivalent and monovalent multispecific complexes and their uses
|
KR101453462B1
(ko)
|
2013-05-16 |
2014-10-23 |
앱클론(주) |
Her2에 특이적으로 결합하는 항체
|
CN106132436B
(zh)
|
2014-02-21 |
2021-06-15 |
Ibc药品公司 |
通过诱导对trop-2表达细胞的免疫应答的疾病疗法
|
US9139649B2
(en)
|
2014-02-25 |
2015-09-22 |
Immunomedics, Inc. |
Humanized anti-CD22 antibody
|
KR102509481B1
(ko)
*
|
2014-04-10 |
2023-03-10 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
규정된 조성물 유전자 변형된 t-세포 생성물
|
EP3129055B1
(de)
|
2014-04-11 |
2020-07-01 |
MedImmune, LLC |
Bispezifische her2-antikörper
|
BR112016024088A2
(pt)
|
2014-04-16 |
2018-06-19 |
Biocon Ltd. |
formulações de proteína estáveis que compreendem um excesso molar de sorbitol
|
US9580495B2
(en)
|
2014-06-24 |
2017-02-28 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
CA3069221C
(en)
|
2014-09-23 |
2023-04-04 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
CN106999517A
(zh)
|
2014-10-07 |
2017-08-01 |
免疫医疗公司 |
抗体‑药物缀合物的新辅助剂用途
|
EA201791366A1
(ru)
|
2014-12-19 |
2018-02-28 |
Чугаи Сейяку Кабусики Кайся |
Антитела к c5 и способы их применения
|
MY181199A
(en)
|
2014-12-19 |
2020-12-21 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
CN107108729A
(zh)
|
2015-02-05 |
2017-08-29 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用
|
BR112017014067B1
(pt)
|
2015-02-27 |
2021-01-12 |
Chugai Seiyaku Kabushiki Kaisha |
usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
|
EP3286224A4
(de)
|
2015-04-22 |
2018-11-14 |
Immunomedics, Inc. |
Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen
|
IL292708B1
(en)
|
2015-05-30 |
2024-04-01 |
Molecular Templates Inc |
Vaccine-free Shiga toxin A subunit scaffolds and cell-targeting molecules containing them
|
KR20180012859A
(ko)
|
2015-06-17 |
2018-02-06 |
제넨테크, 인크. |
항-her2 항체 및 이용 방법
|
PL3313443T3
(pl)
|
2015-06-25 |
2023-11-06 |
Immunomedics, Inc. |
Łączenie przeciwciał anty-hla-dr lub anty-trop-2 z inhibitorami mikrotubuli, inhibitorami parp, 5 inhibitorami kinazy brutona lub inhibitorami 3-kinazy fosfoinozytydu istotnie poprawia wynik terapeutyczny nowotworu
|
SI3316885T1
(sl)
|
2015-07-01 |
2021-09-30 |
Immunomedics, Inc. |
Imunokonjugati protitelo-SN-38 z linkerjem CL2A
|
CN108174604B
(zh)
|
2015-08-07 |
2023-06-23 |
西雅图儿童医院(Dba西雅图儿童研究所) |
用于实体瘤靶向的双特异性car t细胞
|
US11359009B2
(en)
|
2015-12-25 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
KR20230079499A
(ko)
|
2016-08-05 |
2023-06-07 |
추가이 세이야쿠 가부시키가이샤 |
Il-8 관련 질환의 치료용 또는 예방용 조성물
|
CN110291200B
(zh)
|
2016-12-12 |
2024-05-14 |
西雅图儿童医院(Dba西雅图儿童研究所) |
对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
|
CA3047349C
(en)
|
2017-01-17 |
2020-09-22 |
Genentech, Inc. |
Subcutaneous her2 antibody formulations
|
JP7191833B2
(ja)
|
2017-01-30 |
2022-12-19 |
中外製薬株式会社 |
抗スクレロスチン抗体およびその使用
|
RS65204B1
(sr)
|
2017-03-02 |
2024-03-29 |
Genentech Inc |
Adjuvansni tretman her2-pozitivnog raka dojke
|
WO2018158716A1
(en)
|
2017-03-02 |
2018-09-07 |
Cadila Healthcare Limited |
Novel protein drug conjugate formulation
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
AU2018370195B2
(en)
|
2017-11-14 |
2022-01-13 |
Green Cross Lab Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
SG10201801219VA
(en)
|
2018-02-13 |
2019-09-27 |
Agency Science Tech & Res |
Anti-HER2 Antibodies
|
IL268443B1
(en)
|
2018-04-17 |
2024-03-01 |
Molecular Templates Inc |
HER2-targeted molecules containing Shiga toxin subunit A scaffolds, without vaccination
|
EP3560945A1
(de)
|
2018-04-27 |
2019-10-30 |
F. Hoffmann-La Roche AG |
Verfahren zur reinigung von polypeptiden mit polysorbaten
|
AU2021357841A1
(en)
|
2020-10-08 |
2023-06-15 |
Affimed Gmbh |
Trispecific binders
|
WO2022239720A1
(ja)
|
2021-05-10 |
2022-11-17 |
公益財団法人川崎市産業振興財団 |
抗原への結合親和性を低減させた抗体
|
EP4376958A1
(de)
|
2021-07-30 |
2024-06-05 |
Affimed GmbH |
Duplexkörper
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
CA3233696A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|